Mangoceuticals Files Definitive Proxy Statement
Ticker: MGRX · Form: DEF 14A · Filed: May 16, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | DEF 14A |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Mangoceuticals proxy statement is out - time to vote on board and company direction.
AI Summary
Mangoceuticals, Inc. filed its definitive proxy statement on May 16, 2024, for its annual meeting. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and other corporate actions will be presented to stockholders.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders, not a filing that inherently introduces new financial risks.
Key Players & Entities
- Mangoceuticals, Inc. (company) — Registrant
- May 16, 2024 (date) — Filing Date
- Board of Directors (organization) — Governing Body
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals.
Who is the filer of this document?
The filer of this document is Mangoceuticals, Inc.
When was this definitive proxy statement filed?
This definitive proxy statement was filed on May 16, 2024.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's business address?
The company's business address is 15110 DALLAS PKWY, SUITE 600, DALLAS, TX 75248.
Filing Stats: 4,762 words · 19 min read · ~16 pages · Grade level 13.2 · Accepted 2024-05-16 09:19:29
Key Financial Figures
- $0.0001 — issuance of shares of our common stock, $0.0001 par value per share, in excess of 19.99
Filing Documents
- formdef14a.htm (DEF 14A) — 834KB
- formdef14a_001.jpg (GRAPHIC) — 12KB
- formdef14a_002.jpg (GRAPHIC) — 12KB
- formdef14a_003.jpg (GRAPHIC) — 12KB
- proxy_001.jpg (GRAPHIC) — 285KB
- proxy_002.jpg (GRAPHIC) — 299KB
- 0001493152-24-020141.txt ( ) — 1689KB
FORWARD-LOOKING STATEMENTS AND WEBSITE LINKS
FORWARD-LOOKING STATEMENTS AND WEBSITE LINKS 7 INCORPORATION BY REFERENCE 7 VOTING RIGHTS AND PRINCIPAL STOCKHOLDERS 8
Security Ownership of Management and Certain Beneficial Owners and Management
Security Ownership of Management and Certain Beneficial Owners and Management 8 Change of Control 9 CORPORATE GOVERNANCE 9 Family Relationships among Directors and Officers 9 Arrangements between Directors and Officers 9 Involvement in Certain Legal Proceedings 10 Board Leadership Structure 10 Risk Oversight 10 Other Directorships 10 Committees of the Board 11 Board Committee Membership 11 Nominations for Directors 13 Director Independence 13 Stockholder Communications with the Board 14 Policy on Equity Ownership 14 Policy against Hedging 14 Compensation Recovery 14 Code of Ethics 15 Whistleblower Protection Policy 15 Board Diversity Matrix 15 Report of Audit Committee 15 AUDIT COMMITTEE REPORT 16 Table of Contents INFORMATION ABOUT OUR EXECUTIVE OFFICERS AND DIRECTORS 17 Executive Officers 17 Directors and Director Nominees 18 Terms of Office of Officers and Directors 20 EXECUTIVE AND DIRECTOR COMPENSATION 20 Summary Executive Compensation Table 20 Outstanding Equity Awards at Fiscal Year-End 22 Recent Compensation Awards 23 Employment Agreements 23 Potential Payments Upon Termination 29 Compensation of Directors 30 Key Man Insurance 31 Equity Compensation Plan Information 31 2022 Equity Incentive Plan 32 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 33 Related Party Transactions 33 Review, Approval and Ratification of Related Party Transactions 40 PROPOSAL 1 ELECTION OF DIRECTORS 40 General 40 General Director Qualifications 41 What Vote Is Required To Elect the Director Nominees 41 Board Recommendation 41 PROPOSAL 2 SPA NASDAQ PROPOSAL 41 General 41 Securities Purchase Agreement 42 Registration Rights Agreement 43 Description of the Series B Convertible Preferred Stock 44 Warrants 48 Additional Information 49 Reasons for Stockholder Approval and Potential Consequences of Not Approving this Proposal 49